Light chain (AL) Amyloidosis/Primary
Nov 09, 2015
Objective:
Amyloidosis is a term used to describe a group of diseases in which there is an extracellular deposition of amorphous fibrillar proteins known as amyloid…
Oct 21, 2015
Immunoglobulin light chain (AL) amyloidosis, the most common of the systemic amyloidosis, is characterized by the deposition of amyloid fibrils that derive from the…
Oct 19, 2015
It is believed that exercise is beneficial for the general well-being of patients with amyloidosis. If there are amyloid deposits in the heart then exercise should…
Oct 19, 2015
Many patients with AL amyloidosis should limit their fluid intake. This advice is extremely important but is often overlooked. Fluid intake should be steady and…
May 10, 2015
Objective:
Malnutrition is associated with mortality and impaired quality of life (QoL) in systemic immunoglobulin light-chain (AL) amyloidosis. The aim of this…
Sep 17, 2014
The aims of this review were to describe the case of a patient with debilitating neuroarthropathy of the ankles and feet and reveal a primary systemic (amyloid…
Johnson & Johnson Innovative Medicine is leading where medicine is going. Patients inform and inspire our science-based innovations, which continue to change…
Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to…
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The…
